Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Neurocrine Bioscienc (NQ: NBIX ) 147.77 +1.08 (+0.74%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Neurocrine Bioscienc < Previous 1 2 3 4 5 6 7 8 Next > The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product May 13, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Neurocrine Biosciences: Q1 Earnings Insights May 04, 2022 Neurocrine Biosciences (NASDAQ:NBIX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Via Benzinga Neurocrine Biosciences Q1 2022 Earnings Conference Call On May 4, 2022 At 08:00 AM ET April 25, 2022 Neurocrine Biosciences (NASDAQ:NBIX) will host a conference call at 08:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. Via Benzinga What 8 Analyst Ratings Have To Say About Neurocrine Biosciences April 04, 2022 Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings within the last quarter: Via Benzinga The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia March 29, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Analyst Ratings For Neurocrine Biosciences February 01, 2022 Within the last quarter, Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings: Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2022 March 03, 2022 Upgrades For Douglas Emmett Inc (NYSE:DEI), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. For the fourth quarter, Douglas Emmett had an EPS of $0.48,... Via Benzinga Where Neurocrine Biosciences Stands With Analysts February 25, 2022 Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For February 25, 2022 February 25, 2022 Upgrades According to 86 Research, the prior rating for NetEase Inc (NASDAQ:NTES) was changed from Hold to Buy. For the fourth quarter, NetEase had an EPS of $1.56,... Via Benzinga Looking Into Neurocrine Biosciences's Return On Capital Employed February 14, 2022 Benzinga Pro data, Neurocrine Biosciences (NASDAQ:NBIX) reported Q4 sales of $312.00 million. Earnings fell to a loss of $7.30 million, resulting in a 132.44% decrease from last quarter. Via Benzinga Why Neurocrine Biosciences Are Trading Higher Today? February 11, 2022 Neurocrine Biosciences Inc (NASDAQ: NBIX) reported Q4 Ingrezza sales of $301 million, +25% Y/Y, with total prescriptions up 32% Overall sales increased $312.0 million... Via Benzinga The Daily Biotech Pulse: Adcom Recommends Additional Trials For Lilly's Partnered Cancer Drug, Novavax Touts Pediatric Vaccine Data, TC Biopharm IPO February 11, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adcom Rules That Lilly May Have To Conduct Additional Studies For Co-... Via Benzinga Recap: Neurocrine Biosciences Q4 Earnings February 11, 2022 Neurocrine Biosciences (NASDAQ:NBIX) reported its Q4 earnings results on Friday, February 11, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings Neurocrine... Via Benzinga Earnings Scheduled For February 11, 2022 February 11, 2022 Companies Reporting Before The Bell • Mr. Cooper Group (NASDAQ:COOP) is expected to report quarterly earnings at $1.22 per share on revenue of $551.60 million. Via Benzinga A Preview Of Neurocrine Biosciences's Earnings February 10, 2022 Neurocrine Biosciences (NASDAQ:NBIX) is set to give its latest quarterly earnings report on Friday, 2022-02-11. Here's what investors need to know before the announcement. Analysts estimate that... Via Benzinga The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More February 06, 2022 Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big... Via Benzinga 10 Biggest Price Target Changes For Tuesday January 18, 2022 Keybanc raised J.B. Hunt Transport Services, Inc. (NASDAQ: Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2022 January 18, 2022 Upgrades Canaccord Genuity upgraded the previous rating for Fortuna Silver Mines Inc (NYSE: Via Benzinga Xenon Receives $15M Regulatory Milestone Under Epilepsy Pact With Neurocrine January 12, 2022 Xenon Pharmaceuticals Inc's (NASDAQ: XENE) collaboration to develop treatments for epilepsy with Neurocrine Biosciences Inc (NASDAQ: NBIX) achieved a regulatory... Via Benzinga Analyst Ratings For Neurocrine Biosciences January 07, 2022 Over the past 3 months, 9 analysts have published their opinion on Neurocrine Biosciences (NASDAQ: Via Benzinga The Daily Biotech Pulse: Glaukos Gets FDA Nod, Neurocrine Preannounces Soft Ingrezza Sales, 3 IPOs January 07, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hepion's Lead NASH Drug Candidate Gets The Non-Proprietary Name... Via Benzinga Expert Ratings For Neurocrine Biosciences December 08, 2021 Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst rat... Via Benzinga The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom December 08, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-... Via Benzinga Topics Intellectual Property Lawsuit Exposures Financial Intellectual Property Legal Neurocrine's Ingrezza Meets Primary Goal In Phase 3 Study In Patients With Involuntary Muscle Movement December 08, 2021 Neurocrine Biosciences Inc (NASDAQ: NBIX) revealed topline data from its Phase 3 KINECT-HD study evaluating Ingrezza (valbenazine) for chorea associated with... Via Benzinga Neurocrine Pens $2.6B Pact With Sosei Heptares For Neuro Targets November 22, 2021 Neurocrine Biosciences Inc (NASDAQ: NBIX) has outlined a deal that provides Sosei Heptares Corporation $100 million upfront, R&D expenses, and a... Via Benzinga Mobile Mental Health: Coming to a Home Near You? November 18, 2021 Photo by Anna Shvets from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... Via Benzinga Analyst Ratings For Neurocrine Biosciences November 17, 2021 Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst rat... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 November 19, 2021 Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE: Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2021 November 17, 2021 Upgrades According to Williams Capital, the prior rating for On Holding AG (NYSE: Via Benzinga 71 Biggest Movers From Yesterday November 03, 2021 Gainers Avis Budget Group, Inc. (NASDAQ: CAR) shares climbed 108.3% to close at $357.17 on Tuesday after the company reported better-than-expected Q3 adjusted EPS and sales... Via Benzinga < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.